NF1 and neoplasm: For example, trametinib alone resulted in moderate tumor inhibition in NF1-MET tumors (Figure 5A), yet combined trametinib + doxorubicin significantly improved the response in comparison to single-agent treatment with trametinb or doxorubicin (Figure 5B).